Through scientific partnerships with many foreign and Belgian universities, KitoZyme has perfected KiOtransine®
,a new prebiotic which contributes to the restoration of the microbiota equilibrium, without causing adverse reactions to the intestinal system. “Because of our novel patented bio-polymers of fungal origin, non-genetically modified, our company has position itself as an expert in the intestinal microbiota”
said François Blondel, CEO of KitoZyme. This prebiotic, unique in the world and already marketed for several months in the U.S., is now going to be introduced in the European Union. “With this European marketing authorization, we intend initially to develop commercial partnerships in France, Italy, Germany and Poland, for launches in the
pharmacies within the year”, he added.
Simultaneously, KitoZyme continues its scientific research and product development programmes, both for human health and animal nutrition.
The human digestive system is host to thousands of billions of bacteria and other microorganisms, known collectively as the intestinal microbiota, that influence the health and well-being of each individual. There is a broad scientific consensus that an unbalanced intestinal flora can cause serious disorders of the gastrointestinal system such as irritable bowel syndrome, Crohn’s disease, but also diabetes or obesity.